The company announced that it will conduct research based on guidance from the agency.
NRx Pharmaceuticals announced that it has received a response from FDA over its proposed plan to study the impact of ketamine (NRX-100) as a treatment for suicidal depression in adolescents.1 Congress had previously stated that this is a requirement before NRx can filing a new drug application (NDA) for the use of ketamine to treat suicidal depression.
According to NRx, it will work with Hope Therapeutics to conduct a clinical trial on ketamine’s use for this condition. The study will include participants aged 9-17, but it will not be required to include younger participants. The companies will also conduct studies involving animals to determine the safety of ketamine usage in adolescents.
In a press release, NRx Pharmaceuticals chairman and HOPE Therapeutics co-CEO Prof. Jonathan Javitt said, “Youth suicide has reached crisis proportions in the United States with a 62% increase over the past two decades, disproportionately affecting minorities. We appreciate FDA's recognition of the urgent unmet medical need related to suicidal depression in adolescents and look forward to expanding the mission of NRx and HOPE Therapeutics to serve America's youth in preventing needless deaths from suicidal depression.”
NRx also announced that it will proceed with the spinoff of Hope Therapeutics after a Utah arbitrator denied a petition from Streeterville Captial, LLC, to enjoin NRx from spinning off 49% of the shares of HOPE Therapeutics.2
In a press release, Javitt stated, “As we have previously shared with the public, HOPE Therapeutics is in the process of developing a best-in-class network of clinics that currently offer ketamine and other lifesaving therapies to patients with suicidal depression. This arbitration decision enables us to keep our promise to shareholders to spin out 49% of HOPE Therapeutics shares held by NRx to our shareholders, subject to approval by our Board of Directors and compliance with applicable law. We appreciate the support and loyalty of our shareholders as we work to bring HOPE to life.”
NRx announced that it would be filing the NDA for ketamine in June of this year.3 At the time, the company stated that it based its decision on four positive trials.
At the time, Javitt stated, “The NRx team has worked diligently since the end of the COVID pandemic to achieve these milestones for our shareholders and most importantly the patients we have always sought to help. Given the near-term market opportunity represented by an accelerated approval process, NRx anticipates a higher potential return to NRx investors associated with an NRx-led initiative than that which would likely be achieved with a large commercial partner."
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.
FDA Grants Priority Review to GSK’s Gepotidacin for Uncomplicated Urinary Tract Infections
October 18th 2024Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.